| Nov 14 |
AN2 Therapeutics GAAP EPS of -$0.43
|
| Nov 14 |
AN2 Therapeutics to Participate at Upcoming Investor Conferences
|
| Nov 13 |
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
|
| Oct 3 |
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
|
| Aug 28 |
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 19 |
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
|
| Aug 16 |
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
|
| Aug 14 |
AN2 Therapeutics GAAP EPS of -$0.48
|
| Aug 13 |
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
|
| Aug 9 |
Top Midday Decliners
|
